<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590976</url>
  </required_header>
  <id_info>
    <org_study_id>276834</org_study_id>
    <nct_id>NCT04590976</nct_id>
  </id_info>
  <brief_title>Metastatic Prostate Cancer Men's Attitudes Towards Treatment of the Local Tumour and Metastasis Evaluative Research</brief_title>
  <acronym>IP5-MATTER</acronym>
  <official_title>Patients' Preferences in the Treatment of Hormone-sensitive Metastatic Prostate Cancer: a Discrete Choice Experiment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aberdeen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic therapy (i.e Androgen Deprivation Therapy with Docetaxel, Enzalutamide, Apalutamide&#xD;
      or Abiraterone Acetate) has increased overall survival in men with hormone-sensitive&#xD;
      metastatic prostate cancer.&#xD;
&#xD;
      Novel local cytoreductive treatments and metastasis directed therapy are being evaluated,&#xD;
      these can confer additional harm, but might improve survival.&#xD;
&#xD;
      We aim to elicit men's preferences for and willingness to accept trade-offs between potential&#xD;
      improved survival and cytoreductive treatment risks using a 'discrete choice experiment'.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: To determine the attributes associated with treatment that are most important to&#xD;
      men with hormone-sensitive metastatic prostate cancer (mPCa). To determine men's preferences&#xD;
      for, and trade-offs between, the attributes (survival and side-effects) of different&#xD;
      treatment options in metastatic prostate cancer including systemic therapy, local and&#xD;
      metastases-directed physical therapies.&#xD;
&#xD;
      PHASE: Prospective multi-centre observational cohort&#xD;
&#xD;
      DESIGN: Discrete choice experiment, single-visit, electronic questionnaire design&#xD;
&#xD;
      SAMPLE SIZE: Multi-centre Stage (Stage 3) n = 300 patients&#xD;
&#xD;
      POPULATION: Men with newly-diagnosed metastatic prostate cancer who have not consented to a&#xD;
      form of local cytoreductive or metastasis directed therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment attribute preferences as assessed using a study-specific think aloud interview.</measure>
    <time_frame>Through study completion, an average of 3 months [Stage 2] (Think Aloud Interview).</time_frame>
    <description>Qualitative work derived from &quot;Think Aloud Interviews&quot;. Treatments include radiotherapy, surgery, ablation and metastasis directed therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Willingness to accept treatment attributes, and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire</measure>
    <time_frame>Through study completion, an average of 1 year [Stage 3] (Discrete Choice Experiment (DCE) Questionnaire). Trade-off from Marginal Rate of Substitution calculate as percentage points (0 to 100).</time_frame>
    <description>Utility values obtained via multinominal logit estimates from discrete choice experiment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Willingness to accept the potential effect sizes that are shown in trials.</measure>
    <time_frame>Through study completion, an average of 1 year [Stage 3] (Discrete Choice Experiment (DCE) Questionnaire). No scale.</time_frame>
    <description>Derived from discrete choice experiment finding analysed alongside reported outcomes from ongoing therapeutic trials.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Radiotherapy Side Effect</condition>
  <condition>Surgery</condition>
  <condition>Urologic Cancer</condition>
  <condition>Quality of Life</condition>
  <condition>Patient Satisfaction</condition>
  <condition>Health Care Utilization</condition>
  <arm_group>
    <arm_group_label>Healthcare Professionals (n = 5)</arm_group_label>
    <description>Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 (n = 5)</arm_group_label>
    <description>Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 (n = 10)</arm_group_label>
    <description>Intervention: Single, &quot;Think Aloud Interview&quot; Interview. These will be analysed using an inductive thematic analysis by at least two researchers. Common themes will be extracted by researchers individually and then discussed and agreed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3 (n = 300)</arm_group_label>
    <description>Intervention: Single, Discrete Choice Experiment Questionnaire at Enrollment Visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Semi-Structured Interview Healthcare Professional</intervention_name>
    <description>Interview</description>
    <arm_group_label>Healthcare Professionals (n = 5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Semi-Structured Interview Patients</intervention_name>
    <description>Interview</description>
    <arm_group_label>Stage 1 (n = 5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Think Aloud Interview Patients</intervention_name>
    <description>Interview</description>
    <arm_group_label>Stage 2 (n = 10)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Discrete Choice Experiment (DCE) Patients</intervention_name>
    <description>DCE Questionnaire</description>
    <arm_group_label>Stage 3 (n = 300)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men with newly-diagnosed hormone-sensitive metastatic prostate cancer who have not&#xD;
        consented to a form of local cytoreductive or metastasis directed therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with prostate cancer within 4 months of screening visit&#xD;
&#xD;
          2. Performance status 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Castrate-resistant metastatic prostate cancer&#xD;
&#xD;
          2. Patient has consented to a form of local cytoreductive treatment to prostate&#xD;
&#xD;
          3. Patient has consented to a form of metastasis directed therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hashim Ahmed, PhD, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin J Connor, MRCS</last_name>
    <phone>0044203 311 5473</phone>
    <email>m.connor@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hashim U. Ahmed, PhD, FRCS</last_name>
    <phone>0044203 311 5473</phone>
    <email>mattertrial@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Besti Cadwaladr University</name>
      <address>
        <city>Bangor</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iqbal Shergill, FRCS (Urol)</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frimley Health Nhs Foundation Trust</name>
      <address>
        <city>Frimley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Bott, FRCS (Urol)</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>Hammersmith</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin J. Connor, MRCS</last_name>
    </contact>
    <contact_backup>
      <last_name>Hashim U. Ahmed, FRCS (Urol)</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>West Middlesex University Hospital</name>
      <address>
        <city>Isleworth</city>
        <zip>TW7 6AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathias Winkler, FRCS (Urol)</last_name>
    </contact>
    <investigator>
      <last_name>Marthias Winkler, FRCS (Urol)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>King's Lynn</city>
        <zip>PE30 4ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamalram Thippu Jayaprakash, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gail Horan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bijan Khoubehi, FRCS (Urol)</last_name>
    </contact>
    <investigator>
      <last_name>Bijan Khoubehi, FRCS (Urol)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cathryn Brock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin J Connor, MRCS</last_name>
      <phone>0203 311 5473</phone>
      <email>m.connor@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Hashim U. Ahmed, FRCS (Urol)</last_name>
      <email>mattertrial@imperial.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Hashim U. Ahmed, FRCS (Urol)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin J. Connor, MRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathias Winkler, FRCS (Urol)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas Hospital, Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Cathcart, FRCS (Urol)</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust, Chelsea Research Centre</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Khoo, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital, Newcastle, Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bhavan Rai, FRCS (Urol)</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital, University Hospital Southampton NHS Foundation Trust (UHS)</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tim Dudderidge, FRCS (Urol)</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>East and North Hertfordshire Nhs Trust</name>
      <address>
        <city>Stevenage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nikhil Vasdev, FRCS (Urol)</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital, City Hospitals Sunderland NHS Foundation Trust</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stuart McCracken, FRCS (Urol)</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre Nhs Foundation Trust</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ibrahim Azman, FRCR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wirral University Teaching Hospital Nhs Foundation</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manal Kumar, FRCS (Urol)</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

